Literature DB >> 7110912

Cyclosporin A: correlation between HPLC and RIA serum levels.

E Abisch, T Beveridge, A Gratwohl, W Niederberger, K Nussbaumer, P Schaub, B Speck, M Trapp.   

Abstract

Serum levels of cyclosporin A were analysed in parallel with an HPLC and a RIA method for six patients who received repeated intramuscular and oral doses of this immunosuppressive drug after bone marrow transplantation. A good correlation was found between both methods with a similar time course of the serum curves. Due to cross-reacting metabolites, the values from the RIA assay were on average 30 to 100% higher than with the HPLC assay which is specific for the parent drug.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7110912     DOI： 10.1007/bf01962250

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN： 0167-6555


  10 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  [Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity].

Authors:  A Rüegger; M Kuhn; H Lichti; H R Loosli; R Huguenin; C Quiquerez; A von Wartburg
Journal:  Helv Chim Acta       Date:  1976       Impact factor: 2.164

3.  High-performance liquid chromatographic determination of cyclosporin A in human plasma and urine.

Authors:  W Niederberger; P Schaub; T Beveridge
Journal:  J Chromatogr       Date:  1980-06-13

4.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

5.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

6.  Immunological and pharmacological monitoring in the clinical use of cyclosporin A.

Authors:  P A Keown; C R Stiller; R A Ulan; N R Sinclair; W J Wall; G Carruthers; W Howson
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

7.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

8.  Immunosuppression with cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anaemia: preliminary studies.

Authors:  J Hows; R Harris; S Palmer; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

9.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

10.  The use of cyclosporin A and prednisone in cadaver kidney transplantation.

Authors:  T E Starzl; R Weil; S Iwatsuki; G Klintmalm; G P Schröter; L J Koep; Y Iwaki; P I Terasaki; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1980-07
  10 in total
  7 in total

1.  Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients.

Authors:  G Burckart; T Starzl; L Williams; A Sanghvi; C Gartner; R Venkataramanan; B Zitelli; J Malatack; A Urbach; W Diven; R Ptachcinski; B Shaw; S Iwatsuki
Journal:  Transplant Proc       Date:  1985-02       Impact factor: 1.066

2.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

3.  Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

Authors:  P Bertault-Pérès; D Maraninchi; Y Carcassonne; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Excretion of cyclosporine and its metabolites in human bile.

Authors:  G J Burckart; T E Starzl; R Venkataramanan; H Hashim; L Wong; P Wang; L Makowka; A Zeevi; R J Ptachcinski; J E Knapp
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

5.  Cyclosporine trough concentration monitoring in liver transplant patients.

Authors:  G J Burckart; R J Ptachcinski; R Venkataramanan; S Iwatsuki; C Esquivel; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 6.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 7.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.